BEAM · CIK 1745999
What Beam Therapeutics Inc. told the SEC could break it.
1 self-disclosed vulnerability, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far, we surface every cited disclosure we’ve extracted for BEAM. More may follow as additional filings are processed.
In its own words
What could break it.
Regulatory & policy
- 2025 U.S. tariff actions (10% baseline + reciprocal tariffs, 25% Canada/Mexico, 20% China) could raise R&D input/reagent costslow
Beam imports research materials, reagents and equipment and maintains a global patent and research footprint, exposing it to 2025 U.S. trade actions. On April 2, 2025 a 10% baseline reciprocal tariff was announced on all trading partners (effective April 5) plus higher individualized reciprocal tariffs on 57 countries, on top of a 25% tariff on non-USMCA goods from Canada and Mexico and a 20% tariff on imports from China, prompting retaliatory tariffs from Canada and China. While pharmaceutical-related products received certain exemptions and Beam is pre-revenue, escalating tariffs and trade disruptions could increase the cost of its research and manufacturing inputs. Severity is low given the pharma exemptions and the company's pre-commercial stage.
“On April 2, 2025, President Trump issued an executive order announcing a “baseline” reciprocal tariff of 10% on all U.S. trading partners effective April 5, 2025, and higher individualized reciprocal tariffs on 57 countries (with certain product exemptions for pharmaceutical-related products, among others).”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Harvard (President and Fellows of Harvard College)
“We may owe Harvard and Broad Institute success payments of up to an additional $90.0 million each.”
Cited →“We also have approximately 24 pending patent applications between the Broad Institute, Inc., UCL Business, Ltd., and Apellis Pharmaceuticals, Inc.”
Cited →UCL Business, Ltd.
“We also have approximately 24 pending patent applications between the Broad Institute, Inc., UCL Business, Ltd., and Apellis Pharmaceuticals, Inc.”
Cited →The Broad Institute, Inc.
“We may owe Harvard and Broad Institute success payments of up to an additional $90.0 million each.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch